ALNY:NSD-Alnylam Pharmaceuticals, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 160.42

Change

+0.42 (+0.26)%

Market Cap

USD 18.21B

Volume

0.83M

Average Target Price

USD 147.67 (-7.95%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP). In addition, the company is developing givosiran for the treatment of patients with AHP; lumasiran for the treatment of primary hyperoxaluria type 1, or PH1; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Ionis Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals, Inc., as well as collaboration with Vir Biotechnology, Inc. to advance RNAi therapeutics for the treatment of coronavirus infection, including COVID-19. It also has a collaboration and license agreement with Dicerna Pharmaceuticals, Inc. to develop and commercialize investigational ribonucleic acid interference therapeutics for the treatment of alpha-1 antitrypsin deficiency-associated liver disease, as well as Vir Biotechnology, Inc. to develop and commercialize RNAi therapeutics. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-07-08 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

-3.14 (-1.05%)

USD76.11B 50.45 37.87
REGN Regeneron Pharmaceuticals, Inc

-0.54 (-0.08%)

USD65.50B 31.28 21.67
SGEN Seattle Genetics, Inc

-0.61 (-0.35%)

USD30.38B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

-4.46 (-3.97%)

USD23.85B 10.60 9.11
INCY Incyte Corporation

-0.38 (-0.35%)

USD23.62B 47.64 35.20
BMRN BioMarin Pharmaceutical Inc

+0.75 (+0.59%)

USD23.14B 201.24 120.72
MRNA Moderna, Inc

+0.49 (+0.80%)

USD22.86B N/A N/A
GMAB Genmab A/S

+0.86 (+2.50%)

USD22.35B 60.04 6.37
BNTX BioNTech SE

-1.78 (-2.57%)

USD15.72B -99,999.99 N/A
BGNE BeiGene, Ltd

+7.51 (+3.82%)

USD15.64B N/A N/A

ETFs Containing ALNY

Symbol Name Weight Mer Price(Change) Market Cap
BTEC Principal Healthcare Inno.. 2.88 % 0.42 %

+0.74 (+1.63%)

USD0.09B
FXH First Trust Health Care A.. 2.43 % 0.62 %

+0.58 (+0.63%)

USD1.93B
FHH:CA FT AlphaDEX U.S. Health C.. 2.36 % 0.70 %

-0.30 (-0.88%)

USD0.02B
XBI SPDR S&P Biotech ETF 1.88 % 0.35 %

+1.73 (+1.50%)

USD4.91B
ZHU:CA BMO Equal Weight US Healt.. 1.86 % 0.35 %

+0.41 (+1.11%)

USD0.03B
ZUH:CA BMO Equal Weight US Healt.. 1.85 % 0.35 %

+0.12 (+0.19%)

USD0.39B
SCHM Schwab U.S. Mid-Cap ETF 0.54 % 0.04 %

+0.37 (+0.71%)

USD6.06B
IUSZ:LSE iShares Edge MSCI USA Siz.. 0.42 % 0.20 %

-0.11 (-1.61%)

USD0.06B
IWSZ:LSE iShares Edge MSCI World S.. 0.16 % 0.30 %

-0.45 (-1.39%)

USD0.60B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 39.29% 73% C 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 39.29% 73% C 84% B
Trailing 12 Months  
Capital Gain 119.03% 84% B 92% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 119.03% 84% B 92% A-
Trailing 5 Years  
Capital Gain 38.25% 76% C 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 38.25% 75% C 67% D+
Average Annual (5 Year Horizon)  
Capital Gain 26.00% 70% C- 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 26.00% 70% C- 69% D+
Risk Return Profile  
Volatility (Standard Deviation) 77.64% 23% F 10% F
Risk Adjusted Return 33.49% 65% D 42% F
Market Capitalization 18.21B 98% A+ 96% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 12.66 14% F 10% F
Price / Cash Flow Ratio -65.42 97% A+ 95% A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -61.20% 55% F 21% F
Return on Invested Capital -67.88% 46% F 14% F
Return on Assets -27.97% 53% F 15% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 8.60 18% F 11% F
Short Percent 7.06% 42% F 30% F
Beta 1.85 36% F 18% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.